Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Caris Life Sciences' Molecular Intelligence Platform Identifies Patients With MSI-High (Or Mismatch Repair Deficient) Solid Tumors More Likely To Respond To Immunotherapy June 8, 2017 Ovid Release: Company Names M.D., To Scientific Advisory Board January 19, 2017 Genetic Tech Exploring Strategic Alternatives August 24, 2017
Caris Life Sciences' Molecular Intelligence Platform Identifies Patients With MSI-High (Or Mismatch Repair Deficient) Solid Tumors More Likely To Respond To Immunotherapy June 8, 2017
